You are here

  • Home
  • Archive
  • Volume 30, Issue 11
  • Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer

Article metrics

Article menu
Download PDFPDF
Original research
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2023

AbstractFullPdf
Oct 20203361813
Nov 202039495
Dec 202018375
Jan 20216300
Feb 20216510
Mar 20214201
Apr 20214620
May 20211300
Jun 2021221
Jul 2021431
Aug 2021111
Sep 2021110
Oct 20214800
Nov 20215146
Dec 20213400
Jan 20223200
Feb 20228800
Mar 20227221
Apr 20226411
May 20226510
Jun 20227954
Jul 20225040
Aug 20228532
Sep 20226530
Oct 20227322
Nov 20224300
Dec 20224011
Jan 20232200
Feb 20239700
Mar 20233000
Total21887044